A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

In this study, eligible subject to accept study treatment. Camrelizumab combined with apatinib is a treatment cycle every 2 weeks

A Single-arm, Open, Prospective, Single-center, Phase ? Clinical Study of Carilizumab Combined With Apatinib in theTtreatment of Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma and Alveolar Soft Tissue Sarcoma

This study is a Single-arm, Open, Prospective, Single-center, Phase ? Clinical Study ,Target population is Advanced Inoperable Resection of Undifferentiated Pleomorphic Sarcoma (UPS) and Alveolar Soft Tissue Sarcoma (ASPS) . The purpose of this study was to evaluate the safety and efficacy of combination of Camrelizumab and Apatinib in the treatment of unresectable UPS and ASPS

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Recruitment

Summary

Participation Requirements

Description

Tracking Information